GEHC Reports Thursday With Short Interest Rebuilt and Retail Attention Spiking

GE HealthCare Technologies reports Q3 results on Thursday, October 30, with the stock trading at $71.11 after a 1.3% gain on the week, and two separate data points flagging unusual activity in the run-up: short interest has climbed roughly 14% over the past three weeks and retail attention has hit a multi-month extreme.

The short interest story is the more telling of the two. Bears rebuilt positions aggressively between early and mid-October, pushing short interest from around 16.6 million shares on October 8 to a recent peak of 21.2 million on October 23, a 28% jump in a fortnight. The ORTEX daily estimate now reads 19.2 million shares, or 4.2% of the free float, after a partial pullback in the final two sessions of the week. That level is meaningful without being extreme, but the speed of the rebuild is what stands out. The ORTEX short score ticked up to 45.8 on October 23 alongside the peak, before settling back to 42.7 by Tuesday, suggesting some of those positions were tactical rather than structural. Borrow conditions offer no resistance to further shorting: cost to borrow is just 0.46%, and with availability running at roughly 1,343% of outstanding short interest, there is no squeeze pressure in the lending market at all.

Options positioning is calm by comparison. The put/call ratio is 0.70, only modestly above its 20-day average of 0.67 and less than one standard deviation from the mean. The 52-week range runs from 0.48 to 2.22, so the current reading sits in the lower third of that band. Whatever anxiety surrounds Thursday's print is showing up in short positioning, not in hedging through the options market.

The Street is split in a way that captures the stock's central tension. Analyst consensus is broadly constructive, with Barclays initiating at Overweight and an $85 target earlier this month, while Needham holds a Buy with a $93 target. BTIG trimmed its target from $79 to $75 on October 12 but kept its Buy rating, and Citigroup cut to $71 while maintaining Neutral. The mean price target of $83.45 implies roughly 17% upside from current levels. Bulls point to a $23.9 billion backlog, roughly half of revenue being recurring through services and diagnostics, a medium-term operating margin target of 17% to 20%, and the pending Sofie Biosciences acquisition adding a radiopharmaceuticals leg to the portfolio. Bears counter with low-single-digit revenue growth assumptions, hospital capital budget pressure, and China exposure that has dropped from 15% of revenue in 2021 to 11% in 2025 and has been a consistent growth headwind. The PE multiple has expanded about 0.7 points over the past 30 days to 13.4x, and the dividend score ranks in the 88th percentile, which points to institutional comfort with the quality of cash generation even if growth expectations are modest.

Dodge & Cox remains the standout name on the register, having lifted its stake to 10.5% of shares outstanding per a Schedule 13G/A filed in August, up from 8.3% previously. BlackRock and Vanguard entities together account for roughly another 15%. One noteworthy structural change: The Vanguard Group filed a 13G/A in March reporting a position of 0%, down from 11.49%, with Vanguard Capital Management simultaneously filing a fresh 13G at 7.31%. This appears to be an internal reorganisation of how Vanguard books its holdings rather than a genuine exit, but it is worth watching for how the combined Vanguard position evolves in subsequent filings. Insider activity over the past 90 days is effectively neutral. The September transactions were primarily tax-withholding sales tied to vesting events, not open-market disposals, and CFO William Grogan received stock awards of just over 75,000 shares. No discretionary buying or selling is on record.

One additional data point worth flagging ahead of Thursday: Wikipedia page views for GE HealthCare hit a z-score of 4.6 against the company's own 90-day history as of October 19, according to ORTEX Alt Data. That reflects a sharp spike in retail attention around the stock. This is not a revenue indicator and there is no measured relationship between attention levels and the reported financials, but a reading of that magnitude typically signals that a catalyst is pulling in a wider audience than usual. The stock's last reported earnings, in late July, produced a one-day gain of 9.1% and a five-day gain of 9.6%, giving some reference for how the market has responded when results have come in ahead of expectations.

The specific thing to watch on Thursday morning is whether management narrows or maintains its full-year revenue and margin guidance, given the bear case rests almost entirely on China and tariff headwinds continuing to compress the growth outlook into 2027.